TL;DR
The economic engine of major US health insurers is increasingly decoupled from traditional underwriting, relying instead on internal transfer pricing and complex government risk-adjustment pools to secure profitability. While vertical integration allows payers to shift margins into less-regulated clinical and pharmacy services, public exchange strategies are pivoting toward high-acuity populations backed by federal redistribution programs. These maneuvers demonstrate that modern managed care profitability is less about avoiding sick patients and more about mastering regulatory and corporate capital flows.
The Internal Capital Re-routing Playbook
Health insurers are increasingly using internal service divisions to capture less-regulated profits and bypass strict statutory margin caps on their insurance business.
"$10.97 billion (61.0%) of this revenue was classified as 'Eliminations,' representing intersegment transactions where Carelon provided services and products to Elevance's own Health Benefits insurance segment." — Elevance Health: Carelon and the Internal Profit Engine of Vertical Integration
This internal routing demonstrates that managed care organizations are not merely insurance underwriters; they are integrated conglomerates that systematically shift margin from capped insurance entities into more lucrative, unregulated service arms. By paying themselves for pharmacy benefit management and clinical care, these firms capture a substantial portion of their overall operating gains—amounting to 32.8% for Elevance—within their own subsidiaries, according to their Q1 2026 SEC filing.
What to watch: Watch whether Carelon Services can maintain its premium margin as it expands clinical and behavioral services to Elevance's internal member pool.
Navigating the Risk-Pool Arbitrage
Large payers are shifting their public exchange strategies to embrace higher-acuity members, betting that federal risk-adjustment programs will yield higher margins than standard premiums.
"We have not accounted for the full range of what that receivable could be in the updated guidance, but that range does wrap around our original 4% target margin for 2026 in Marketplace and frankly higher than that at the top end." — Centene: Marketplace Risk Adjustment and the June Wakely Consulting Catalyst
Centene's deliberate decision to cap its immediate margin guidance reflects a calculated gamble on ACA risk pools. Despite experiencing a 36.4% year-over-year drop in Marketplace enrollment, the high-acuity silver-tier members who remained could trigger a massive risk-adjustment receivable, potentially netting the company up to $95 million in pre-tax margin for every marginal improvement in their health benefit ratio, as outlined in their Q1 2026 earnings call.
What to watch: Watch the release of the June Wakely National Risk Adjustment Reporting data to see if Centene's silver-tier morbidity successfully triggers the anticipated payout.
What surprised us
- Elevance's Carelon is quietly carrying nearly a third of the company's profitability. While public and regulatory scrutiny focuses heavily on insurance premium hikes, Elevance's Q1 2026 financial results show that its Carelon services and PBM segments captured 32.8% of the company's total segment operating gains
. This proves that the core insurance margin is intentionally kept thin to comply with regulatory caps, while the real profits are generated by vertically integrated service segments.
- Centene's massive enrollment drop is actually a margin-boosting strategy in disguise. Conventional wisdom says a 36.4% decline in Marketplace enrollment
is a disaster, but Centene's remaining members are sicker, silver-tier individuals. Far from a headwind, Centene is leveraging this high-acuity book to capture a substantial risk-adjustment receivable from healthier competitors, showing that in government-sponsored markets, sicker members can sometimes be more lucrative than healthy ones.
- The "Eliminations" line is the most important number on the balance sheet. In a single quarter, Elevance classified 61.0% of Carelon's revenue as intersegment eliminations
Open threads worth a vote
- Centene June 2026 Wakely Risk Adjustment Data Release: Vote to prioritize our coverage of the upcoming Wakely data release, which will determine whether Centene's high-acuity silver-tier strategy pays off or triggers a costly risk-adjustment payable.
- CMS Star Ratings October 2026 Announcement: Help us steer our tracking of Humana and UnitedHealth's Medicare Advantage margin recovery pathways as the critical October star ratings approach.